Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting

被引:4
作者
Frezza, Anna Maria [1 ]
Stacchiotti, Silvia [1 ]
Gronchi, Alessandro [2 ]
机构
[1] Fdn IRCCS Ist Nazl Tumori, Dept Canc Med, Milan, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Via Venezian 1, I-20133 Milan, Italy
来源
BMC MEDICINE | 2017年 / 15卷
关键词
Sarcoma; Gastrointestinal stromal tumours; Prognostic assessment; Preoperative treatment; Chemotherapy; Antiangiogenic drugs; Immunotherapy; Next generation sequencing;
D O I
10.1186/s12916-017-0931-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Herein, we summarise the results of the most relevant studies presented at the 2017 ASCO Annual Meeting in the field of soft tissue sarcomas (STSs) and gastrointestinal stromal tumours (GISTs). Innovations on the management of localised disease, highlights from the different experiences in the metastatic setting and large studies on rare histologies will be included. Special attention will be paid to results on immunotherapy, antiangiogenics use in histology with limited sensitivity to standard chemotherapy and new compounds. The preliminary results on the impact of the next generation sequencing in the everyday management of STS and GIST patients will be also discussed.
引用
收藏
页数:5
相关论文
共 22 条
  • [1] Attia S, 2017, J CLIN ONCOL S, V35
  • [2] Broto JM, 2017, J CLIN ONCOL S, V35
  • [3] Predicting overall survival in patients (pts) with treatment-naive metastatic Merkel cell carcinoma (mMCC) treated with avelumab.
    Bullement, Ash
    D'Angelo, Sandra P.
    Amin, Amerah
    Stapelkamp, Ceilidh
    Willis, Anna
    Lilley, Cameron
    Hatswell, Anthony
    Bharmal, Murtuza
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.
    Burgess, Melissa Amber
    Roszik, Jason
    Van Tine, Brian Andrew
    Hu, James
    Schuetze, Scott
    D'Angelo, Sandra P.
    Attia, Steven
    Priebat, Dennis A.
    Okuno, Scott H.
    Riedel, Richard F.
    Davis, Lara Emily
    Movva, Sujana
    Reed, Damon R.
    Baker, Laurence H.
    Reinke, Denise K.
    Maki, Robert G.
    Patel, Shreyaskumar
    Tawbi, Hussein Abdul-Hassan
    Butterfield, Lisa Helene
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [5] Chakravarty D, 2017, JCO PRECIS ONCOL, V1
  • [6] Chawla SP, 2017, J CLIN ONCOL S, V35
  • [7] Administration of aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas.
    Eilber, Frederick C.
    Sankhala, Kamalesh Kumar
    Chawla, Sant P.
    Chua-Alcaia, Victoria S.
    Gordon, Erlinda Maria
    Quon, Doris
    Kim, Katherine
    Chawla, Shanta
    Wu, Nancy
    Wieland, Scott
    Levitt, Daniel J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] NY-ESO-1 (CTAG1B) expression in mesenchymal tumors
    Endo, Makoto
    de Graaff, Marieke A.
    Ingram, Davis R.
    Lim, Simin
    Lev, Dina C.
    Riaire-de Bruijn, Inge H.
    Somaiah, Neeta
    Bovee, Judith V. M. G.
    Lazar, Alexander J.
    Nielseni, Torsten O.
    [J]. MODERN PATHOLOGY, 2015, 28 (04) : 587 - 595
  • [9] Anthracycline, gemacitabine, and pazopanib in epithelioid sarcoma: Results of a retrospective multi-institutional case series.
    Frezza, Anna Maria
    Asano, Naofumi
    Jones, Robin
    Ratan, Ravin
    Teterycz, Pawel
    Gelderblom, Hans
    Boye, Kjetil
    Brahmi, Mehdi
    Palmerini, Emanuela
    Hindi, Nadia
    Brunello, Antonella
    Desar, Ingrid
    Grignani, Giovanni
    Fedenko, Alexander A.
    Vincenzi, Bruno
    Papai, Zsuzsanna
    Kawai, Akira
    Lo Vullo, Salvatore
    Casali, Paolo Giovanni
    Stacchiotti, Silvia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Gounder NM, 2017, J CLIN ONCOL S, V35